Company: EVGN
Filing Date: 2025-09-30
Form Type: POS AM
Source: 0001178913-25-003429
Chunk: 6

Company: Evogene Ltd.
Filing Date: 2025-09-30
Form: POS AM
Chunk 6
---
 is 50 Library Avenue, Suite 204, Newark, Delaware 19711, United States.

2

THE OFFERING

| Ordinary shares outstanding as of the date of this prospectus |     | 8,716,410 ordinary shares (as of September 1, 2025).                                                                                                                                                                                       |
| Ordinary shares offered by the Selling Shareholder            |     | 3,384,616 ordinary shares, constituting the ordinary shares underlying the Series A warrants and the Series B warrants, or, together, the ordinary warrants, issued by us to the Selling                                                   
 Shareholder in the August 26, 2024 private placement.                                                                                                                                                                                      
 Each ordinary warrant has an exercise price per share of $3.55 and was exercisable immediately upon issuance. The Series A warrants will expire on the five-year anniversary of the date                                                   
 of issuance (i.e., on August 26, 2029), while the Series B warrants will expire on the 18-month anniversary of the date of issuance (i.e., on February 26, 2026).                                                                          |
| Ordinary shares to beoutstanding after this offering (1)      |     | 12,101,026 ordinary shares, assuming the exercise in full of all 3,384,616 of the  ordinary warrants for cash and without adjustment.                                                                                                      |
| Use of proceeds                                               |     | The Selling Shareholder will receive all of the proceeds from the sale of any ordinary shares sold by it pursuant to this prospectus. We will not receive any proceeds from the sale of                                                    
 the ordinary shares by the Selling Shareholder (although we may receive proceeds from any exercise of the ordinary warrants, to the extent such warrants are exercised by the Selling Shareholder). See “Use of Proceeds” in this          
 prospectus.                                                                                                                                                                                                                                |
| Listing                                                       |     | Our ordinary shares are listed for trading on the Nasdaq Capital Market and on the TASE, in each case under the symbol “EVGN”.                                                                                                             |
| Risk Factors                                                  |     | Investing in our securities is highly speculative and involves substantial risk.You should carefully consider all the information in this                                                                                                  
 prospectus prior to investing in our securities. In particular, we urge you to consider carefully the factors set forth in the section of this prospectus entitled “Risk Factors” beginning on page 4, including the risks described under 
 the heading “Item 3 Key Information - D. Risk Factors” in our 2024 annual report, which we filed with the SEC